Late detection of cancer is a major contributor to the deadliness of this disease. The mission of SPAGO Imaging is to enable the visualization of smaller tumors with greater specificity than we can today. This will save lives and suffering.

SPAGO Imaging is developing a proprietary contrast agent for MRI, which is showing great promise in achieving this goal
June 28, 2010
Sensational Enhancement. SPAGO Imaging has now confirmed that the relaxivity (t1)of our nanoparticles is reliably more than 50/mmol Gd/s (at 2 T) as compared to the marketed contrast agents hovering around 4/mmol Gd/s. The relaxivity determines how much the MRI images are enhanced. In combination with the large number of gadolinium ions in each particle this enables the long sought technique of MR targeting with a positive contrast agent suitable for use in humans. We have reason to believe this breakthrough will lead to spectacular images in the near future. We also believe this will translate to better clinical tumor diagnostics so we can help saving lives and reduce suffering.

March 29, 2010
SPAGO Imaging AB omnämns positivt i Veckans Affärer http://www.va.se/nyheter/2010/03/25/framkantsteknik-till-fyndpris/

March 12, 2010
SPAGO Imaging has recruited Jörgen Buus Lassen to the Board of Directors. Jörgen Buus Lassen D.V.M. has over 25 years of experience in pharmaceutical research. He is a co-founder and former CEO of NeuroSearch, a Danish pharmaceutical company with a stock market value of approximately SEK 5.5 billion (2010-03-12).

created by papillion